2型糖尿病的综合临床风险预测,具有多因素多基因风险评分
Scott C Ritchie1,2,3,4,5,6, Henry J Taylor3,4,7, Yujian Liang8
1Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
一个新的多基因风险评分 (PRS) 开发了2型糖尿病 (T2D),使用不同的遗传数据和风险因素. 这种metaPRS改善了T2D预测和风险分层,在祖先之间表现出强的表现.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 流行病学 流行病学
- 个性化医疗是个性化的医疗.
背景情况:
- 2型糖尿病 (T2D) 是一种复杂的多基因疾病.
- 为T2D开发准确的多基因风险评分 (PRS) 是一个挑战.
- 整合不同的遗传祖先和风险因素可以增强PRS的实用性.
研究的目的:
- 开发和评估一种用于T2D预测的新型元PRS.
- 评估metaPRS在不同人群中的可转移性和预测能力.
- 为了确定metaPRS是否改善了临床环境中的T2D风险分层.
主要方法:
- 使用meta-scoring方法创建了一个T2D metaPRS.
- 包括来自欧洲和非欧洲祖先的全基因组关联数据和T2D风险因素.
- 评估了超过62万名参与者的表现,包括英国生物银行在内的多个队列.
主要成果:
- 开发的metaPRS在欧洲队列中展示了对T2D的优越预测能力.
- 它的性能与祖先特定的PRS相比,显示出良好的可转移性.
- 超越个人因素,metaPRS增强了10年T2D风险预测,并适度改善了现有的临床风险得分.
结论:
- 为T2D开发了一种高度预测和可转移的metaPRS.
- 这个metaPRS在T2D风险预测方面提供了增量改进.
- 将metaPRS纳入临床指南可以加强T2D查和风险分层.
更多相关视频
09:52Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Polygenic Traits
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
